PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2014

Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways.

Mixed / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 25386226 ↗2014Reported benefit

Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways.

MixedChemical/toxinC57BL/6 (mice); Sprague-Dawley (neonatal rats)Male (mice); not stated for neonatal ratsn = 60 mice randomly divided into 3 groups of 20; separate retr…Oral gavage (in vivo); culture medium (in vitro)1.5 g/kg in vivo; 50 microg/mL in vitroPretreatment for 3 days before doxorubicin injection, continued for 3 days afte…

Model: Doxorubicin-induced cardiotoxicity and heart failure, single intraperitoneal dose of doxorubicin 20 mg/kg; in vitro doxorubicin exposure of neonatal rat ventricular myocytes for 24 h

Astragalus polysaccharide pretreatment reduced doxorubicin-induced reactive oxygen species, cardiomyocyte apoptosis and caspase activation and attenuated the fall in ejection fraction and fractional shortening, with increased Akt and suppressed p38MAPK phosphorylation.

Extraction: extract · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.